Condition
Neurological Manifestations
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 3 (1)
Trial Status
Recruiting2
Completed1
Unknown1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06891443Phase 3Recruiting
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
NCT06653647Not ApplicableCompleted
Efficacy of Guided Imagery Therapy Mobile Application for Functional Abdominal Pain
NCT07205861Recruiting
Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center
NCT04546737Not ApplicableUnknown
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
NCT00137527Not ApplicableTerminatedPrimary
Brain Oxygenation Monitoring in Patients Undergoing Coronary Artery Bypass Surgery
Showing all 5 trials